nodes	percent_of_prediction	percent_of_DWPC	metapath
Loratadine—atopic dermatitis—psoriasis	0.62	1	CtDrD
Loratadine—CYP2C8—Tazarotene—psoriasis	0.0343	0.118	CbGbCtD
Loratadine—CYP2D6—Hydroxyurea—psoriasis	0.0154	0.0532	CbGbCtD
Loratadine—CYP2C8—Cholecalciferol—psoriasis	0.0146	0.0505	CbGbCtD
Loratadine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0127	0.0438	CbGbCtD
Loratadine—CYP2C19—Cholecalciferol—psoriasis	0.0123	0.0424	CbGbCtD
Loratadine—CYP3A4—Calcitriol—psoriasis	0.0115	0.0398	CbGbCtD
Loratadine—CYP2C9—Cholecalciferol—psoriasis	0.0102	0.0353	CbGbCtD
Loratadine—CYP2C8—Hydrocortisone—psoriasis	0.0102	0.0352	CbGbCtD
Loratadine—CYP2C8—Cyclosporine—psoriasis	0.00961	0.0332	CbGbCtD
Loratadine—CYP2D6—Cholecalciferol—psoriasis	0.00933	0.0322	CbGbCtD
Loratadine—CYP3A4—Methoxsalen—psoriasis	0.00895	0.0309	CbGbCtD
Loratadine—ABCB1—Mycophenolate mofetil—psoriasis	0.00858	0.0297	CbGbCtD
Loratadine—CYP2C19—Prednisone—psoriasis	0.0085	0.0294	CbGbCtD
Loratadine—CYP2C19—Cyclosporine—psoriasis	0.00806	0.0279	CbGbCtD
Loratadine—ABCB1—Betamethasone—psoriasis	0.00736	0.0254	CbGbCtD
Loratadine—ABCB1—Prednisolone—psoriasis	0.00726	0.0251	CbGbCtD
Loratadine—ABCB1—Hydrocortisone—psoriasis	0.00689	0.0238	CbGbCtD
Loratadine—ABCB1—Prednisone—psoriasis	0.00686	0.0237	CbGbCtD
Loratadine—CYP2C9—Cyclosporine—psoriasis	0.0067	0.0232	CbGbCtD
Loratadine—ABCB1—Cyclosporine—psoriasis	0.0065	0.0225	CbGbCtD
Loratadine—CYP2C8—Dexamethasone—psoriasis	0.00633	0.0219	CbGbCtD
Loratadine—CYP2D6—Cyclosporine—psoriasis	0.00613	0.0212	CbGbCtD
Loratadine—CYP3A4—Cholecalciferol—psoriasis	0.00593	0.0205	CbGbCtD
Loratadine—CYP2C19—Dexamethasone—psoriasis	0.00531	0.0183	CbGbCtD
Loratadine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00514	0.0178	CbGbCtD
Loratadine—CYP3A4—Triamcinolone—psoriasis	0.00514	0.0178	CbGbCtD
Loratadine—CYP2C9—Dexamethasone—psoriasis	0.00441	0.0153	CbGbCtD
Loratadine—CYP3A4—Betamethasone—psoriasis	0.00441	0.0152	CbGbCtD
Loratadine—CYP3A4—Prednisolone—psoriasis	0.00435	0.015	CbGbCtD
Loratadine—ABCB1—Dexamethasone—psoriasis	0.00428	0.0148	CbGbCtD
Loratadine—CYP3A4—Hydrocortisone—psoriasis	0.00413	0.0143	CbGbCtD
Loratadine—CYP3A4—Prednisone—psoriasis	0.00411	0.0142	CbGbCtD
Loratadine—CYP2D6—Dexamethasone—psoriasis	0.00404	0.0139	CbGbCtD
Loratadine—CYP3A4—Cyclosporine—psoriasis	0.0039	0.0135	CbGbCtD
Loratadine—ABCB1—Methotrexate—psoriasis	0.00344	0.0119	CbGbCtD
Loratadine—CYP3A4—Dexamethasone—psoriasis	0.00257	0.00887	CbGbCtD
Loratadine—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000496	0.0644	CbGpPWpGaD
Loratadine—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000443	0.0575	CbGpPWpGaD
Loratadine—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000407	0.0529	CbGpPWpGaD
Loratadine—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000404	0.0524	CbGpPWpGaD
Loratadine—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00038	0.0493	CbGpPWpGaD
Loratadine—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000308	0.0399	CbGpPWpGaD
Loratadine—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000275	0.0356	CbGpPWpGaD
Loratadine—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000253	0.0328	CbGpPWpGaD
Loratadine—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00025	0.0325	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL22—psoriasis	0.000215	0.0279	CbGpPWpGaD
Loratadine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000165	0.0214	CbGpPWpGaD
Loratadine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000128	0.0166	CbGpPWpGaD
Loratadine—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000126	0.0164	CbGpPWpGaD
Loratadine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000114	0.0148	CbGpPWpGaD
Loratadine—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000113	0.0146	CbGpPWpGaD
Loratadine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000105	0.0136	CbGpPWpGaD
Loratadine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000104	0.0135	CbGpPWpGaD
Loratadine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000104	0.0134	CbGpPWpGaD
Loratadine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000104	0.0134	CbGpPWpGaD
Loratadine—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000103	0.0133	CbGpPWpGaD
Loratadine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	9.24e-05	0.012	CbGpPWpGaD
Loratadine—Anaphylactic shock—Prednisolone—psoriasis	8.94e-05	0.00108	CcSEcCtD
Loratadine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	8.9e-05	0.0116	CbGpPWpGaD
Loratadine—Insomnia—Cyclosporine—psoriasis	8.88e-05	0.00107	CcSEcCtD
Loratadine—Loss of consciousness—Triamcinolone—psoriasis	8.85e-05	0.00107	CcSEcCtD
Loratadine—Paraesthesia—Cyclosporine—psoriasis	8.82e-05	0.00107	CcSEcCtD
Loratadine—Shock—Prednisolone—psoriasis	8.79e-05	0.00106	CcSEcCtD
Loratadine—Cough—Triamcinolone—psoriasis	8.79e-05	0.00106	CcSEcCtD
Loratadine—Somnolence—Cyclosporine—psoriasis	8.73e-05	0.00106	CcSEcCtD
Loratadine—KCNH2—SIDS Susceptibility Pathways—RUNX3—psoriasis	8.73e-05	0.0113	CbGpPWpGaD
Loratadine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	8.73e-05	0.00106	CcSEcCtD
Loratadine—Anaphylactic shock—Hydrocortisone—psoriasis	8.73e-05	0.00106	CcSEcCtD
Loratadine—Tachycardia—Prednisolone—psoriasis	8.72e-05	0.00105	CcSEcCtD
Loratadine—Asthenia—Mycophenolic acid—psoriasis	8.71e-05	0.00105	CcSEcCtD
Loratadine—Hypertension—Triamcinolone—psoriasis	8.69e-05	0.00105	CcSEcCtD
Loratadine—Insomnia—Mycophenolate mofetil—psoriasis	8.66e-05	0.00105	CcSEcCtD
Loratadine—Dyspepsia—Cyclosporine—psoriasis	8.64e-05	0.00105	CcSEcCtD
Loratadine—Nausea—Hydroxyurea—psoriasis	8.61e-05	0.00104	CcSEcCtD
Loratadine—Paraesthesia—Mycophenolate mofetil—psoriasis	8.6e-05	0.00104	CcSEcCtD
Loratadine—Shock—Hydrocortisone—psoriasis	8.59e-05	0.00104	CcSEcCtD
Loratadine—Myalgia—Triamcinolone—psoriasis	8.57e-05	0.00104	CcSEcCtD
Loratadine—Nervous system disorder—Hydrocortisone—psoriasis	8.56e-05	0.00103	CcSEcCtD
Loratadine—Tachycardia—Hydrocortisone—psoriasis	8.52e-05	0.00103	CcSEcCtD
Loratadine—Somnolence—Mycophenolate mofetil—psoriasis	8.52e-05	0.00103	CcSEcCtD
Loratadine—Drowsiness—Methotrexate—psoriasis	8.51e-05	0.00103	CcSEcCtD
Loratadine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.5e-05	0.011	CbGpPWpGaD
Loratadine—Depression—Methotrexate—psoriasis	8.48e-05	0.00103	CcSEcCtD
Loratadine—Gastrointestinal disorder—Cyclosporine—psoriasis	8.48e-05	0.00102	CcSEcCtD
Loratadine—Skin disorder—Hydrocortisone—psoriasis	8.48e-05	0.00102	CcSEcCtD
Loratadine—Ill-defined disorder—Dexamethasone—psoriasis	8.48e-05	0.00102	CcSEcCtD
Loratadine—Ill-defined disorder—Betamethasone—psoriasis	8.48e-05	0.00102	CcSEcCtD
Loratadine—Discomfort—Triamcinolone—psoriasis	8.47e-05	0.00102	CcSEcCtD
Loratadine—Fatigue—Cyclosporine—psoriasis	8.47e-05	0.00102	CcSEcCtD
Loratadine—Dyspepsia—Mycophenolate mofetil—psoriasis	8.43e-05	0.00102	CcSEcCtD
Loratadine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	8.43e-05	0.0109	CbGpPWpGaD
Loratadine—Pain—Cyclosporine—psoriasis	8.4e-05	0.00102	CcSEcCtD
Loratadine—Constipation—Cyclosporine—psoriasis	8.4e-05	0.00102	CcSEcCtD
Loratadine—Dry mouth—Triamcinolone—psoriasis	8.38e-05	0.00101	CcSEcCtD
Loratadine—Angioedema—Dexamethasone—psoriasis	8.35e-05	0.00101	CcSEcCtD
Loratadine—Angioedema—Betamethasone—psoriasis	8.35e-05	0.00101	CcSEcCtD
Loratadine—Diarrhoea—Mycophenolic acid—psoriasis	8.31e-05	0.001	CcSEcCtD
Loratadine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.27e-05	0.001	CcSEcCtD
Loratadine—Immune system disorder—Prednisone—psoriasis	8.26e-05	0.000998	CcSEcCtD
Loratadine—Malaise—Dexamethasone—psoriasis	8.24e-05	0.000996	CcSEcCtD
Loratadine—Malaise—Betamethasone—psoriasis	8.24e-05	0.000996	CcSEcCtD
Loratadine—Anaphylactic shock—Triamcinolone—psoriasis	8.22e-05	0.000993	CcSEcCtD
Loratadine—Syncope—Betamethasone—psoriasis	8.19e-05	0.000991	CcSEcCtD
Loratadine—Syncope—Dexamethasone—psoriasis	8.19e-05	0.000991	CcSEcCtD
Loratadine—Constipation—Mycophenolate mofetil—psoriasis	8.19e-05	0.00099	CcSEcCtD
Loratadine—Pain—Mycophenolate mofetil—psoriasis	8.19e-05	0.00099	CcSEcCtD
Loratadine—Arrhythmia—Prednisone—psoriasis	8.16e-05	0.000987	CcSEcCtD
Loratadine—Hypotension—Hydrocortisone—psoriasis	8.15e-05	0.000986	CcSEcCtD
Loratadine—Feeling abnormal—Cyclosporine—psoriasis	8.09e-05	0.000978	CcSEcCtD
Loratadine—Shock—Triamcinolone—psoriasis	8.08e-05	0.000977	CcSEcCtD
Loratadine—Insomnia—Prednisolone—psoriasis	8.08e-05	0.000977	CcSEcCtD
Loratadine—Alopecia—Prednisone—psoriasis	8.08e-05	0.000976	CcSEcCtD
Loratadine—Hepatobiliary disease—Methotrexate—psoriasis	8.05e-05	0.000973	CcSEcCtD
Loratadine—Gastrointestinal pain—Cyclosporine—psoriasis	8.03e-05	0.000971	CcSEcCtD
Loratadine—Loss of consciousness—Betamethasone—psoriasis	8.03e-05	0.000971	CcSEcCtD
Loratadine—Loss of consciousness—Dexamethasone—psoriasis	8.03e-05	0.000971	CcSEcCtD
Loratadine—Dizziness—Mycophenolic acid—psoriasis	8.03e-05	0.00097	CcSEcCtD
Loratadine—Epistaxis—Methotrexate—psoriasis	8.03e-05	0.00097	CcSEcCtD
Loratadine—Paraesthesia—Prednisolone—psoriasis	8.02e-05	0.00097	CcSEcCtD
Loratadine—Tachycardia—Triamcinolone—psoriasis	8.02e-05	0.00097	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.95e-05	0.000961	CcSEcCtD
Loratadine—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.89e-05	0.000954	CcSEcCtD
Loratadine—Insomnia—Hydrocortisone—psoriasis	7.89e-05	0.000954	CcSEcCtD
Loratadine—Hypertension—Betamethasone—psoriasis	7.89e-05	0.000954	CcSEcCtD
Loratadine—Hypertension—Dexamethasone—psoriasis	7.89e-05	0.000954	CcSEcCtD
Loratadine—Paraesthesia—Hydrocortisone—psoriasis	7.84e-05	0.000947	CcSEcCtD
Loratadine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.83e-05	0.000947	CcSEcCtD
Loratadine—Myalgia—Dexamethasone—psoriasis	7.78e-05	0.00094	CcSEcCtD
Loratadine—Myalgia—Betamethasone—psoriasis	7.78e-05	0.00094	CcSEcCtD
Loratadine—Abdominal pain—Cyclosporine—psoriasis	7.76e-05	0.000939	CcSEcCtD
Loratadine—Body temperature increased—Cyclosporine—psoriasis	7.76e-05	0.000939	CcSEcCtD
Loratadine—Vomiting—Mycophenolic acid—psoriasis	7.72e-05	0.000933	CcSEcCtD
Loratadine—Discomfort—Betamethasone—psoriasis	7.68e-05	0.000929	CcSEcCtD
Loratadine—Discomfort—Dexamethasone—psoriasis	7.68e-05	0.000929	CcSEcCtD
Loratadine—Dyspepsia—Hydrocortisone—psoriasis	7.68e-05	0.000929	CcSEcCtD
Loratadine—Rash—Mycophenolic acid—psoriasis	7.65e-05	0.000925	CcSEcCtD
Loratadine—Dermatitis—Mycophenolic acid—psoriasis	7.65e-05	0.000924	CcSEcCtD
Loratadine—Pain—Prednisolone—psoriasis	7.64e-05	0.000924	CcSEcCtD
Loratadine—Headache—Mycophenolic acid—psoriasis	7.6e-05	0.000919	CcSEcCtD
Loratadine—Pharyngitis—Methotrexate—psoriasis	7.58e-05	0.000917	CcSEcCtD
Loratadine—Abdominal pain—Mycophenolate mofetil—psoriasis	7.57e-05	0.000916	CcSEcCtD
Loratadine—Body temperature increased—Mycophenolate mofetil—psoriasis	7.57e-05	0.000916	CcSEcCtD
Loratadine—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.53e-05	0.000911	CcSEcCtD
Loratadine—Fatigue—Hydrocortisone—psoriasis	7.52e-05	0.00091	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.49e-05	0.000905	CcSEcCtD
Loratadine—Pain—Hydrocortisone—psoriasis	7.46e-05	0.000902	CcSEcCtD
Loratadine—Anaphylactic shock—Betamethasone—psoriasis	7.46e-05	0.000901	CcSEcCtD
Loratadine—Anaphylactic shock—Dexamethasone—psoriasis	7.46e-05	0.000901	CcSEcCtD
Loratadine—Insomnia—Triamcinolone—psoriasis	7.43e-05	0.000899	CcSEcCtD
Loratadine—Ill-defined disorder—Prednisone—psoriasis	7.38e-05	0.000892	CcSEcCtD
Loratadine—Paraesthesia—Triamcinolone—psoriasis	7.38e-05	0.000892	CcSEcCtD
Loratadine—Feeling abnormal—Prednisolone—psoriasis	7.36e-05	0.00089	CcSEcCtD
Loratadine—Shock—Betamethasone—psoriasis	7.34e-05	0.000887	CcSEcCtD
Loratadine—Shock—Dexamethasone—psoriasis	7.34e-05	0.000887	CcSEcCtD
Loratadine—Nervous system disorder—Dexamethasone—psoriasis	7.31e-05	0.000884	CcSEcCtD
Loratadine—Nervous system disorder—Betamethasone—psoriasis	7.31e-05	0.000884	CcSEcCtD
Loratadine—Agitation—Prednisone—psoriasis	7.31e-05	0.000884	CcSEcCtD
Loratadine—Tachycardia—Betamethasone—psoriasis	7.28e-05	0.00088	CcSEcCtD
Loratadine—Tachycardia—Dexamethasone—psoriasis	7.28e-05	0.00088	CcSEcCtD
Loratadine—Angioedema—Prednisone—psoriasis	7.27e-05	0.000879	CcSEcCtD
Loratadine—Dyspepsia—Triamcinolone—psoriasis	7.23e-05	0.000875	CcSEcCtD
Loratadine—Nausea—Mycophenolic acid—psoriasis	7.21e-05	0.000872	CcSEcCtD
Loratadine—Feeling abnormal—Hydrocortisone—psoriasis	7.19e-05	0.000869	CcSEcCtD
Loratadine—Malaise—Prednisone—psoriasis	7.17e-05	0.000867	CcSEcCtD
Loratadine—Gastrointestinal pain—Hydrocortisone—psoriasis	7.14e-05	0.000863	CcSEcCtD
Loratadine—Syncope—Prednisone—psoriasis	7.13e-05	0.000863	CcSEcCtD
Loratadine—Tinnitus—Methotrexate—psoriasis	7.12e-05	0.000861	CcSEcCtD
Loratadine—Fatigue—Triamcinolone—psoriasis	7.08e-05	0.000857	CcSEcCtD
Loratadine—Asthenia—Cyclosporine—psoriasis	7.05e-05	0.000852	CcSEcCtD
Loratadine—Pain—Triamcinolone—psoriasis	7.03e-05	0.00085	CcSEcCtD
Loratadine—Loss of consciousness—Prednisone—psoriasis	6.99e-05	0.000845	CcSEcCtD
Loratadine—Hypotension—Dexamethasone—psoriasis	6.97e-05	0.000842	CcSEcCtD
Loratadine—Hypotension—Betamethasone—psoriasis	6.97e-05	0.000842	CcSEcCtD
Loratadine—Immune system disorder—Methotrexate—psoriasis	6.9e-05	0.000834	CcSEcCtD
Loratadine—Abdominal pain—Hydrocortisone—psoriasis	6.9e-05	0.000834	CcSEcCtD
Loratadine—Body temperature increased—Hydrocortisone—psoriasis	6.9e-05	0.000834	CcSEcCtD
Loratadine—KCNH2—SIDS Susceptibility Pathways—IL13—psoriasis	6.89e-05	0.00895	CbGpPWpGaD
Loratadine—Asthenia—Mycophenolate mofetil—psoriasis	6.87e-05	0.000831	CcSEcCtD
Loratadine—Hypertension—Prednisone—psoriasis	6.87e-05	0.00083	CcSEcCtD
Loratadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	6.86e-05	0.0089	CbGpPWpGaD
Loratadine—Musculoskeletal discomfort—Betamethasone—psoriasis	6.79e-05	0.000821	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.79e-05	0.000821	CcSEcCtD
Loratadine—Myalgia—Prednisone—psoriasis	6.77e-05	0.000819	CcSEcCtD
Loratadine—Feeling abnormal—Triamcinolone—psoriasis	6.77e-05	0.000819	CcSEcCtD
Loratadine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	6.77e-05	0.00878	CbGpPWpGaD
Loratadine—Alopecia—Methotrexate—psoriasis	6.75e-05	0.000816	CcSEcCtD
Loratadine—Insomnia—Dexamethasone—psoriasis	6.74e-05	0.000815	CcSEcCtD
Loratadine—Insomnia—Betamethasone—psoriasis	6.74e-05	0.000815	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.73e-05	0.000813	CcSEcCtD
Loratadine—Diarrhoea—Cyclosporine—psoriasis	6.72e-05	0.000812	CcSEcCtD
Loratadine—Paraesthesia—Betamethasone—psoriasis	6.7e-05	0.000809	CcSEcCtD
Loratadine—Paraesthesia—Dexamethasone—psoriasis	6.7e-05	0.000809	CcSEcCtD
Loratadine—Discomfort—Prednisone—psoriasis	6.69e-05	0.000809	CcSEcCtD
Loratadine—Dyspepsia—Dexamethasone—psoriasis	6.56e-05	0.000794	CcSEcCtD
Loratadine—Dyspepsia—Betamethasone—psoriasis	6.56e-05	0.000794	CcSEcCtD
Loratadine—Diarrhoea—Mycophenolate mofetil—psoriasis	6.55e-05	0.000792	CcSEcCtD
Loratadine—Dysgeusia—Methotrexate—psoriasis	6.51e-05	0.000787	CcSEcCtD
Loratadine—Body temperature increased—Triamcinolone—psoriasis	6.5e-05	0.000785	CcSEcCtD
Loratadine—Dizziness—Cyclosporine—psoriasis	6.49e-05	0.000785	CcSEcCtD
Loratadine—Anaphylactic shock—Prednisone—psoriasis	6.49e-05	0.000785	CcSEcCtD
Loratadine—Gastrointestinal disorder—Betamethasone—psoriasis	6.44e-05	0.000778	CcSEcCtD
Loratadine—Gastrointestinal disorder—Dexamethasone—psoriasis	6.44e-05	0.000778	CcSEcCtD
Loratadine—Fatigue—Betamethasone—psoriasis	6.43e-05	0.000777	CcSEcCtD
Loratadine—Fatigue—Dexamethasone—psoriasis	6.43e-05	0.000777	CcSEcCtD
Loratadine—Shock—Prednisone—psoriasis	6.39e-05	0.000772	CcSEcCtD
Loratadine—Pain—Dexamethasone—psoriasis	6.38e-05	0.000771	CcSEcCtD
Loratadine—Pain—Betamethasone—psoriasis	6.38e-05	0.000771	CcSEcCtD
Loratadine—Nervous system disorder—Prednisone—psoriasis	6.37e-05	0.00077	CcSEcCtD
Loratadine—Tachycardia—Prednisone—psoriasis	6.34e-05	0.000766	CcSEcCtD
Loratadine—Dizziness—Mycophenolate mofetil—psoriasis	6.33e-05	0.000766	CcSEcCtD
Loratadine—Skin disorder—Prednisone—psoriasis	6.31e-05	0.000763	CcSEcCtD
Loratadine—Asthenia—Hydrocortisone—psoriasis	6.26e-05	0.000757	CcSEcCtD
Loratadine—Vomiting—Cyclosporine—psoriasis	6.24e-05	0.000755	CcSEcCtD
Loratadine—Rash—Cyclosporine—psoriasis	6.19e-05	0.000749	CcSEcCtD
Loratadine—Dermatitis—Cyclosporine—psoriasis	6.19e-05	0.000748	CcSEcCtD
Loratadine—Ill-defined disorder—Methotrexate—psoriasis	6.17e-05	0.000746	CcSEcCtD
Loratadine—Headache—Cyclosporine—psoriasis	6.15e-05	0.000744	CcSEcCtD
Loratadine—Feeling abnormal—Dexamethasone—psoriasis	6.14e-05	0.000743	CcSEcCtD
Loratadine—Feeling abnormal—Betamethasone—psoriasis	6.14e-05	0.000743	CcSEcCtD
Loratadine—Gastrointestinal pain—Betamethasone—psoriasis	6.1e-05	0.000737	CcSEcCtD
Loratadine—Gastrointestinal pain—Dexamethasone—psoriasis	6.1e-05	0.000737	CcSEcCtD
Loratadine—Vomiting—Mycophenolate mofetil—psoriasis	6.09e-05	0.000736	CcSEcCtD
Loratadine—HRH1—IL-4 Signaling Pathway—SOCS1—psoriasis	6.07e-05	0.00788	CbGpPWpGaD
Loratadine—Rash—Mycophenolate mofetil—psoriasis	6.04e-05	0.00073	CcSEcCtD
Loratadine—Dermatitis—Mycophenolate mofetil—psoriasis	6.03e-05	0.00073	CcSEcCtD
Loratadine—Headache—Mycophenolate mofetil—psoriasis	6e-05	0.000726	CcSEcCtD
Loratadine—Malaise—Methotrexate—psoriasis	6e-05	0.000725	CcSEcCtD
Loratadine—Diarrhoea—Hydrocortisone—psoriasis	5.97e-05	0.000722	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Prednisone—psoriasis	5.92e-05	0.000715	CcSEcCtD
Loratadine—Dizziness—Prednisolone—psoriasis	5.91e-05	0.000714	CcSEcCtD
Loratadine—Asthenia—Triamcinolone—psoriasis	5.9e-05	0.000713	CcSEcCtD
Loratadine—Body temperature increased—Dexamethasone—psoriasis	5.89e-05	0.000713	CcSEcCtD
Loratadine—Abdominal pain—Dexamethasone—psoriasis	5.89e-05	0.000713	CcSEcCtD
Loratadine—Abdominal pain—Betamethasone—psoriasis	5.89e-05	0.000713	CcSEcCtD
Loratadine—Body temperature increased—Betamethasone—psoriasis	5.89e-05	0.000713	CcSEcCtD
Loratadine—Insomnia—Prednisone—psoriasis	5.87e-05	0.00071	CcSEcCtD
Loratadine—Nausea—Cyclosporine—psoriasis	5.83e-05	0.000705	CcSEcCtD
Loratadine—Paraesthesia—Prednisone—psoriasis	5.83e-05	0.000705	CcSEcCtD
Loratadine—Cough—Methotrexate—psoriasis	5.8e-05	0.000701	CcSEcCtD
Loratadine—Dizziness—Hydrocortisone—psoriasis	5.77e-05	0.000698	CcSEcCtD
Loratadine—Dyspepsia—Prednisone—psoriasis	5.72e-05	0.000691	CcSEcCtD
Loratadine—Nausea—Mycophenolate mofetil—psoriasis	5.69e-05	0.000688	CcSEcCtD
Loratadine—Myalgia—Methotrexate—psoriasis	5.66e-05	0.000684	CcSEcCtD
Loratadine—Chest pain—Methotrexate—psoriasis	5.66e-05	0.000684	CcSEcCtD
Loratadine—Rash—Prednisolone—psoriasis	5.63e-05	0.000681	CcSEcCtD
Loratadine—Dermatitis—Prednisolone—psoriasis	5.63e-05	0.000681	CcSEcCtD
Loratadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.62e-05	0.00068	CcSEcCtD
Loratadine—Fatigue—Prednisone—psoriasis	5.6e-05	0.000677	CcSEcCtD
Loratadine—Headache—Prednisolone—psoriasis	5.6e-05	0.000677	CcSEcCtD
Loratadine—Discomfort—Methotrexate—psoriasis	5.59e-05	0.000676	CcSEcCtD
Loratadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	5.56e-05	0.00722	CbGpPWpGaD
Loratadine—Constipation—Prednisone—psoriasis	5.55e-05	0.000671	CcSEcCtD
Loratadine—Vomiting—Hydrocortisone—psoriasis	5.55e-05	0.000671	CcSEcCtD
Loratadine—Rash—Hydrocortisone—psoriasis	5.5e-05	0.000665	CcSEcCtD
Loratadine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	5.5e-05	0.00714	CbGpPWpGaD
Loratadine—Dermatitis—Hydrocortisone—psoriasis	5.5e-05	0.000665	CcSEcCtD
Loratadine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	5.48e-05	0.00712	CbGpPWpGaD
Loratadine—Headache—Hydrocortisone—psoriasis	5.47e-05	0.000661	CcSEcCtD
Loratadine—Dizziness—Triamcinolone—psoriasis	5.43e-05	0.000657	CcSEcCtD
Loratadine—Anaphylactic shock—Methotrexate—psoriasis	5.43e-05	0.000656	CcSEcCtD
Loratadine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	5.43e-05	0.00704	CbGpPWpGaD
Loratadine—Feeling abnormal—Prednisone—psoriasis	5.35e-05	0.000647	CcSEcCtD
Loratadine—Asthenia—Dexamethasone—psoriasis	5.35e-05	0.000647	CcSEcCtD
Loratadine—Asthenia—Betamethasone—psoriasis	5.35e-05	0.000647	CcSEcCtD
Loratadine—Nervous system disorder—Methotrexate—psoriasis	5.32e-05	0.000643	CcSEcCtD
Loratadine—Gastrointestinal pain—Prednisone—psoriasis	5.31e-05	0.000642	CcSEcCtD
Loratadine—Nausea—Prednisolone—psoriasis	5.31e-05	0.000642	CcSEcCtD
Loratadine—HRH1—IL-4 Signaling Pathway—IL4—psoriasis	5.3e-05	0.00688	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	5.28e-05	0.00685	CbGpPWpGaD
Loratadine—Skin disorder—Methotrexate—psoriasis	5.27e-05	0.000637	CcSEcCtD
Loratadine—Vomiting—Triamcinolone—psoriasis	5.22e-05	0.000632	CcSEcCtD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	5.21e-05	0.00676	CbGpPWpGaD
Loratadine—Nausea—Hydrocortisone—psoriasis	5.18e-05	0.000627	CcSEcCtD
Loratadine—Rash—Triamcinolone—psoriasis	5.18e-05	0.000626	CcSEcCtD
Loratadine—Dermatitis—Triamcinolone—psoriasis	5.18e-05	0.000626	CcSEcCtD
Loratadine—Headache—Triamcinolone—psoriasis	5.15e-05	0.000622	CcSEcCtD
Loratadine—Body temperature increased—Prednisone—psoriasis	5.13e-05	0.000621	CcSEcCtD
Loratadine—Abdominal pain—Prednisone—psoriasis	5.13e-05	0.000621	CcSEcCtD
Loratadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.11e-05	0.00664	CbGpPWpGaD
Loratadine—Diarrhoea—Betamethasone—psoriasis	5.1e-05	0.000617	CcSEcCtD
Loratadine—Diarrhoea—Dexamethasone—psoriasis	5.1e-05	0.000617	CcSEcCtD
Loratadine—Hypotension—Methotrexate—psoriasis	5.07e-05	0.000613	CcSEcCtD
Loratadine—Musculoskeletal discomfort—Methotrexate—psoriasis	4.94e-05	0.000598	CcSEcCtD
Loratadine—Dizziness—Dexamethasone—psoriasis	4.93e-05	0.000596	CcSEcCtD
Loratadine—Dizziness—Betamethasone—psoriasis	4.93e-05	0.000596	CcSEcCtD
Loratadine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	4.91e-05	0.00637	CbGpPWpGaD
Loratadine—Insomnia—Methotrexate—psoriasis	4.91e-05	0.000593	CcSEcCtD
Loratadine—Nausea—Triamcinolone—psoriasis	4.88e-05	0.00059	CcSEcCtD
Loratadine—Paraesthesia—Methotrexate—psoriasis	4.87e-05	0.000589	CcSEcCtD
Loratadine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	4.84e-05	0.00629	CbGpPWpGaD
Loratadine—Somnolence—Methotrexate—psoriasis	4.82e-05	0.000583	CcSEcCtD
Loratadine—Dyspepsia—Methotrexate—psoriasis	4.78e-05	0.000578	CcSEcCtD
Loratadine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.78e-05	0.0062	CbGpPWpGaD
Loratadine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	4.76e-05	0.00618	CbGpPWpGaD
Loratadine—Vomiting—Dexamethasone—psoriasis	4.74e-05	0.000573	CcSEcCtD
Loratadine—Vomiting—Betamethasone—psoriasis	4.74e-05	0.000573	CcSEcCtD
Loratadine—Rash—Betamethasone—psoriasis	4.7e-05	0.000568	CcSEcCtD
Loratadine—Rash—Dexamethasone—psoriasis	4.7e-05	0.000568	CcSEcCtD
Loratadine—Dermatitis—Dexamethasone—psoriasis	4.7e-05	0.000568	CcSEcCtD
Loratadine—Dermatitis—Betamethasone—psoriasis	4.7e-05	0.000568	CcSEcCtD
Loratadine—Gastrointestinal disorder—Methotrexate—psoriasis	4.68e-05	0.000566	CcSEcCtD
Loratadine—Fatigue—Methotrexate—psoriasis	4.68e-05	0.000566	CcSEcCtD
Loratadine—Headache—Betamethasone—psoriasis	4.67e-05	0.000565	CcSEcCtD
Loratadine—Headache—Dexamethasone—psoriasis	4.67e-05	0.000565	CcSEcCtD
Loratadine—Asthenia—Prednisone—psoriasis	4.66e-05	0.000563	CcSEcCtD
Loratadine—Pain—Methotrexate—psoriasis	4.64e-05	0.000561	CcSEcCtD
Loratadine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	4.52e-05	0.00586	CbGpPWpGaD
Loratadine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	4.48e-05	0.00581	CbGpPWpGaD
Loratadine—Feeling abnormal—Methotrexate—psoriasis	4.47e-05	0.000541	CcSEcCtD
Loratadine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	4.45e-05	0.00578	CbGpPWpGaD
Loratadine—Diarrhoea—Prednisone—psoriasis	4.44e-05	0.000537	CcSEcCtD
Loratadine—Gastrointestinal pain—Methotrexate—psoriasis	4.44e-05	0.000536	CcSEcCtD
Loratadine—Nausea—Dexamethasone—psoriasis	4.43e-05	0.000535	CcSEcCtD
Loratadine—Nausea—Betamethasone—psoriasis	4.43e-05	0.000535	CcSEcCtD
Loratadine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	4.42e-05	0.00573	CbGpPWpGaD
Loratadine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	4.38e-05	0.00568	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—IL10—psoriasis	4.31e-05	0.0056	CbGpPWpGaD
Loratadine—Dizziness—Prednisone—psoriasis	4.29e-05	0.000519	CcSEcCtD
Loratadine—Body temperature increased—Methotrexate—psoriasis	4.29e-05	0.000519	CcSEcCtD
Loratadine—Abdominal pain—Methotrexate—psoriasis	4.29e-05	0.000519	CcSEcCtD
Loratadine—HRH1—IL-4 Signaling Pathway—NFKBIA—psoriasis	4.18e-05	0.00542	CbGpPWpGaD
Loratadine—Vomiting—Prednisone—psoriasis	4.13e-05	0.000499	CcSEcCtD
Loratadine—Rash—Prednisone—psoriasis	4.09e-05	0.000495	CcSEcCtD
Loratadine—Dermatitis—Prednisone—psoriasis	4.09e-05	0.000495	CcSEcCtD
Loratadine—ABCB1—Allograft Rejection—HLA-C—psoriasis	4.07e-05	0.00529	CbGpPWpGaD
Loratadine—Headache—Prednisone—psoriasis	4.07e-05	0.000492	CcSEcCtD
Loratadine—ABCB1—Allograft Rejection—IL13—psoriasis	4.05e-05	0.00526	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—HCAR2—psoriasis	3.96e-05	0.00515	CbGpPWpGaD
Loratadine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—psoriasis	3.93e-05	0.00511	CbGpPWpGaD
Loratadine—Asthenia—Methotrexate—psoriasis	3.89e-05	0.000471	CcSEcCtD
Loratadine—Nausea—Prednisone—psoriasis	3.86e-05	0.000466	CcSEcCtD
Loratadine—ABCB1—Allograft Rejection—IL17A—psoriasis	3.73e-05	0.00484	CbGpPWpGaD
Loratadine—Diarrhoea—Methotrexate—psoriasis	3.71e-05	0.000449	CcSEcCtD
Loratadine—Dizziness—Methotrexate—psoriasis	3.59e-05	0.000434	CcSEcCtD
Loratadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.56e-05	0.00463	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL12B—psoriasis	3.46e-05	0.0045	CbGpPWpGaD
Loratadine—Vomiting—Methotrexate—psoriasis	3.45e-05	0.000417	CcSEcCtD
Loratadine—Rash—Methotrexate—psoriasis	3.42e-05	0.000414	CcSEcCtD
Loratadine—HRH1—IL-4 Signaling Pathway—TYK2—psoriasis	3.42e-05	0.00444	CbGpPWpGaD
Loratadine—Dermatitis—Methotrexate—psoriasis	3.42e-05	0.000413	CcSEcCtD
Loratadine—Headache—Methotrexate—psoriasis	3.4e-05	0.000411	CcSEcCtD
Loratadine—ABCB1—Allograft Rejection—HLA-E—psoriasis	3.38e-05	0.00439	CbGpPWpGaD
Loratadine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.33e-05	0.00432	CbGpPWpGaD
Loratadine—Nausea—Methotrexate—psoriasis	3.22e-05	0.00039	CcSEcCtD
Loratadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	3.15e-05	0.00409	CbGpPWpGaD
Loratadine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	2.95e-05	0.00383	CbGpPWpGaD
Loratadine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	2.91e-05	0.00378	CbGpPWpGaD
Loratadine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	2.83e-05	0.00368	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	2.8e-05	0.00363	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	2.7e-05	0.00351	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—NFKB1—psoriasis	2.67e-05	0.00346	CbGpPWpGaD
Loratadine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	2.6e-05	0.00338	CbGpPWpGaD
Loratadine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	2.55e-05	0.00331	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL10—psoriasis	2.53e-05	0.00329	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IL4—psoriasis	2.46e-05	0.0032	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-B—psoriasis	2.41e-05	0.00313	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	2.41e-05	0.00312	CbGpPWpGaD
Loratadine—HRH1—IL-4 Signaling Pathway—STAT3—psoriasis	2.4e-05	0.00311	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	2.36e-05	0.00306	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	2.24e-05	0.00291	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—HCAR2—psoriasis	2.24e-05	0.00291	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-A—psoriasis	2.23e-05	0.0029	CbGpPWpGaD
Loratadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.2e-05	0.00285	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	2.19e-05	0.00284	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.11e-05	0.00274	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CCL20—psoriasis	2.06e-05	0.00267	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	2.04e-05	0.00265	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—HCAR2—psoriasis	2.03e-05	0.00264	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	1.91e-05	0.00249	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	1.64e-05	0.00213	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—IFNG—psoriasis	1.49e-05	0.00193	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	1.49e-05	0.00193	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—CXCL8—psoriasis	1.39e-05	0.0018	CbGpPWpGaD
Loratadine—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	1.32e-05	0.00172	CbGpPWpGaD
Loratadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	1.3e-05	0.00169	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—HCAR2—psoriasis	1.2e-05	0.00156	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CCL20—psoriasis	1.16e-05	0.00151	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.14e-05	0.00148	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	1.13e-05	0.00147	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.13e-05	0.00146	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—NDUFA5—psoriasis	1.11e-05	0.00144	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CCL20—psoriasis	1.06e-05	0.00137	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TAGAP—psoriasis	1.04e-05	0.00135	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.03e-05	0.00134	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—NDUFA5—psoriasis	9.88e-06	0.00128	CbGpPWpGaD
Loratadine—ABCB1—Allograft Rejection—TNF—psoriasis	9.64e-06	0.00125	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—NDUFA5—psoriasis	9.64e-06	0.00125	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	9.59e-06	0.00124	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CYP2S1—psoriasis	9.41e-06	0.00122	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.21e-06	0.0012	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—NDUFA5—psoriasis	9.08e-06	0.00118	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—NDUFA5—psoriasis	9e-06	0.00117	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	8.96e-06	0.00116	CbGpPWpGaD
Loratadine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	8.55e-06	0.00111	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CYP2S1—psoriasis	8.4e-06	0.00109	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	8.4e-06	0.00109	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CYP2S1—psoriasis	8.2e-06	0.00106	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CYP2S1—psoriasis	7.72e-06	0.001	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CYP2S1—psoriasis	7.66e-06	0.000994	CbGpPWpGaD
Loratadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	7.3e-06	0.000948	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.35e-06	0.000825	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CCL20—psoriasis	6.24e-06	0.00081	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.12e-06	0.000794	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—NDUFA5—psoriasis	5.94e-06	0.000771	CbGpPWpGaD
Loratadine—HRH1—GPCR ligand binding—CXCL8—psoriasis	5.56e-06	0.000722	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.55e-06	0.000721	CbGpPWpGaD
Loratadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	5.54e-06	0.000719	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CYP2S1—psoriasis	5.05e-06	0.000656	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.93e-06	0.00064	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.76e-06	0.000618	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CARM1—psoriasis	4.59e-06	0.000596	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.4e-06	0.000571	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.29e-06	0.000557	CbGpPWpGaD
Loratadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.19e-06	0.000545	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CARM1—psoriasis	4.1e-06	0.000532	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.01e-06	0.000521	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CARM1—psoriasis	4e-06	0.00052	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.83e-06	0.000498	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CARM1—psoriasis	3.77e-06	0.00049	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CARM1—psoriasis	3.74e-06	0.000485	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.5e-06	0.000454	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—SOCS1—psoriasis	3.44e-06	0.000446	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—TYK2—psoriasis	3.28e-06	0.000426	CbGpPWpGaD
Loratadine—HRH1—GPCR downstream signaling—CXCL8—psoriasis	3.14e-06	0.000408	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—CXCL8—psoriasis	2.85e-06	0.00037	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—CAT—psoriasis	2.83e-06	0.000367	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—APOE—psoriasis	2.54e-06	0.000329	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—LEP—psoriasis	2.54e-06	0.000329	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—CAT—psoriasis	2.52e-06	0.000327	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CARM1—psoriasis	2.47e-06	0.00032	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—CAT—psoriasis	2.46e-06	0.00032	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—NFKBIA—psoriasis	2.36e-06	0.000307	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—CAT—psoriasis	2.32e-06	0.000301	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—CAT—psoriasis	2.3e-06	0.000299	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—APOE—psoriasis	2.2e-06	0.000285	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—APOE—psoriasis	1.96e-06	0.000254	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TYK2—psoriasis	1.94e-06	0.000251	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—APOE—psoriasis	1.91e-06	0.000248	CbGpPWpGaD
Loratadine—CYP2C8—Metabolism—PPARG—psoriasis	1.91e-06	0.000248	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—APOE—psoriasis	1.8e-06	0.000234	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—APOE—psoriasis	1.79e-06	0.000232	CbGpPWpGaD
Loratadine—CYP2C19—Metabolism—PPARG—psoriasis	1.71e-06	0.000222	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—CXCL8—psoriasis	1.69e-06	0.000219	CbGpPWpGaD
Loratadine—ABCB1—Metabolism—PPARG—psoriasis	1.67e-06	0.000216	CbGpPWpGaD
Loratadine—HRH1—Signaling by GPCR—IL6—psoriasis	1.6e-06	0.000208	CbGpPWpGaD
Loratadine—CYP2D6—Metabolism—PPARG—psoriasis	1.57e-06	0.000204	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—JUN—psoriasis	1.57e-06	0.000203	CbGpPWpGaD
Loratadine—CYP2C9—Metabolism—PPARG—psoriasis	1.56e-06	0.000202	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—CAT—psoriasis	1.52e-06	0.000197	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—NFKB1—psoriasis	1.51e-06	0.000196	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—VEGFA—psoriasis	1.37e-06	0.000178	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—STAT3—psoriasis	1.36e-06	0.000176	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—APOE—psoriasis	1.18e-06	0.000153	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—TP53—psoriasis	1.03e-06	0.000134	CbGpPWpGaD
Loratadine—CYP3A4—Metabolism—PPARG—psoriasis	1.03e-06	0.000133	CbGpPWpGaD
Loratadine—HRH1—Signaling Pathways—IL6—psoriasis	9.47e-07	0.000123	CbGpPWpGaD
